Seth Keller, MD
Clinical Cardiac Electrophysiology · New York, NYNPI 1598764946
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $96,520 of the $115,276 with a category attached, or 83.7%. Johnson & Johnson accounts for 85.9% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2022 at $32,788 and has fallen 91.9% since, to $2,657 in 2025.
Across 665 payments — averaging $173.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$99K
- Abbott$7K
- Medtronic$2K
- Boston Scientific$1K
- Sanofi-aventis U.S. LLC$1K
- Bardy Diagnostics, Inc.$951
- plus $3K from 16 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$96,52084%
- Travel & lodging$1,2241%
- Food & beverage$16,90515%
- Education$3280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 109 | $99,030 |
| Abbott | 261 | $7,308 |
| Medtronic(2 entities) | 69 | $2,417 |
| Boston Scientific | 75 | $1,397 |
| Sanofi-aventis U.S. LLC | 26 | $1,039 |
| Bardy Diagnostics, Inc. | 15 | $951 |
| Biotronik Inc. | 29 | $820 |
| Pfizer | 34 | $681 |
| Stereotaxis Inc | 6 | $510 |
| Kestra Medical Technology Services, Inc. | 6 | $200 |
| Novartis | 11 | $193 |
| E.r. Squibb & Sons, L.L.C. | 8 | $141 |
| Cvrx, Inc. | 3 | $123 |
| Biosense Webster, Inc. | 1 | $119 |
| Vivaquant Inc, Dba Rhythm Express | 2 | $113 |
| Supernus Pharmaceuticals, Inc. | 3 | $66 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $52 |
| Jazz Pharmaceuticals Inc. | 1 | $36 |
| Medicomp Inc | 1 | $22 |
| Altathera Pharmaceuticals LLC | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Amgen | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$98,029
- LINQ II$1,084
- AVEIR$875
- MULTAQ$450
- Carnation Ambulatory Monitor$378
- GALLANT$363
- Fortify Assura$317
- Quadra Assura CRT Defibrillator$272
- Allure CRT Pacemaker$223
- Rivacor$176
- BioMonitor$176
- Solia$176
- Edora$176
- Acticor$176
- QUADRA ASSURA$168
- Confirm Rx$148
- ASSURITY$133
- Fortify Assura, Ellipse ICD$126
- ELIQUIS$125
- MERLIN@HOME$124
How this compares
$115,276 in reported general payments places this provider in the 85th percentile of 214 clinical cardiac electrophysiology providers in New York.
See all clinical cardiac electrophysiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 161 | $115,781 |
| XareltoRivaroxaban | 102 | $70,521 |
| MultaqDronedarone Hcl | 62 | $60,203 |
| EntrestoSacubitril/Valsartan | 17 | $15,422 |
| Amiodarone Hcl | 71 | $655 |
| Metoprolol Succinate | 63 | $507 |
| Atorvastatin Calcium | 31 | $232 |
| Carvedilol | 43 | $194 |
| Metoprolol Tartrate | 30 | $100 |
| Losartan Potassium | 16 | $61 |
| Furosemide | 22 | $38 |
| Amlodipine Besylate | 12 | $34 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $681 | $115,781161 claims |
| Johnson & JohnsonXarelto | $99,030 | $70,521102 claims |
| Sanofi-aventis U.S. LLCMultaq | $1,039 | $60,20362 claims |
| NovartisEntresto | $193 | $15,42217 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 214 clinical cardiac electrophysiology providers in New York.
Other clinical cardiac electrophysiology in New York
- Vivek ReddyNew York$14.9M
- Jacob KoruthNew York$3.7M
- Srinivas DukkipatiNew York$2.7M
- Amir AhmadiNew York$789K
- Larry ChinitzNew York$448K
- James IpNew York$347K
- Nicholas SkipitarisNew York$293K
- Mohit TuragamNew York$202K
- David LauNew York$202K
- Christopher LiuNew York$181K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.